[1] |
中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2012年版)[J].中华血液学杂志,2012,33(11):975-977.
|
[2] |
顾史洋,庄静丽,邹善华,等.重组人血小板生成素联合糖皮质激素治疗重症新诊断原发免疫性血小板减少症患者临床观察[J].中华血液学杂志,2013,34(10):883-886.
|
[3] |
杜以萍,张充力,毕珍宁.糖皮质激素联合重组人促血小板生成素治疗特发性血小板减少性紫癜[J].血栓与止血学,2014,20(2):79-80.
|
[4] |
支雅军,乐静,万斌,等.重组人血小板生成素联合糖皮质激素治疗难治性特发性血小板减少性紫癜的疗效观察[J].现代实用医学,2013,25(4):417-418.
|
[5] |
郑迎春,李佳慧.特发性血小板减少性紫癜诊断和治疗效果探讨[J].中国继续医学教育,2016,8(28):201-202.
|
[6] |
McMIllan R,Wang L,Tomer A,ET AL.Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP[J].Blood,2004,103(4):1364-1369.
|
[7] |
Molineux G,Newland A.Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside[J].Br J Haematol,2010,150(1):9-20.
|
[8] |
Saleh MN,Bussel JB,Cheng G,et al.Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term,open-lable EXTEND study[J].Blood,2013,121(3):537-545.
|
[9] |
Wang S,Yang R,Zhou P,et al.A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J].Int J Hematol,2012,96(2):222-228.
|
[10] |
Provan D Stasi R,Newland AC,et al.International consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood,2010,118(2):168-186.
|
[11] |
Bussel JB,Kuter DJ,Pullarkat V,et al.Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP[J].Blood,2009,113(10):2161-2171.
|
[12] |
刘隽,程毅敏,邹丽芳,等.重组人血小板生成素治疗老年慢性免疫性血小板减少性紫癜的疗效观察[J].中国临床医学,2013,20(3):390-392.
|
[13] |
徐颜美,邓立彬,王小中.原发免疫性血小板减少性紫癜的遗传学研究进展[J].重庆医学,2014,43(13):1646-1648.
|
[14] |
孔凡霞,陈晓乐,杜秋香,等.重组人血小板生成素联合糖皮质激素和环胞素A治疗免疫性血小板减少症的研究[J].中国医学装备,2015,12(5):36-38.
|
[15] |
王厚才.免疫性血小板减少性紫癜发病的免疫机制[J].国际输血及血液学杂志,2011,34(3):127.
|
[18] |
Gernsheimer T.Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis[J].Oncologist,2009,14(1):12-21.
|
[16] |
Rocha AMC,Souza C,Rocha G A,et al.The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia[J].Haematologica,2011,9600(10):1560-1564.
|
[17] |
Olsson B,Andersson PO,Jernas M,et al.T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J].Nat Med,2003,9(9):1123-1124.
|